|Bid price||0.00||Open price||0.00|
|Ask price||0.00||Prev close||122.00|
Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.
Register now for FREE Vectura Group share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B01D1K48|
|Activites||Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.||Index||n/a|
|Latest Share Price (p)||0.00||Net Gearing (%)||-0.13|
|Market Capitalisation (£m)||480.94||Gross Gearing (%)||26.40|
|Shares in issue (m)||402.46||Debt Ratio||22.10|
|P/E Ratio||-170.71||Debt-to-Equity Ratio||0.79|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.36|
|Dividend Yield (%)||0.00||Price to book value||2.12|
|Dividend cover (x)||0.00||ROCE||-0.03|
|Earning per share (p)||-0.70||EPS Growth (%)||61.11|
|52 week high / low||171.50 / 101.00||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|08/07/2014||BUY||Dr Christopher Blackwell||CEO||1,212|
|08/07/2014||BUY||Dr Trevor Phillips||ED||1,212|
Vectura Group has confirmed that its partner, Sandoz, has been granted marketing authorisation by the regulatory authorities in Ireland and the Czech Republic for AirFluSal®Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The...
/* */ RNS Number : 4389X Vectura Group plc 19 November 2014 Vectura Group plc Approval in Ireland and Czech Republic for innovative respiratory inhaler AirFluSal ® Forspiro ® ...
Investec has upgraded its recommendation on respiratory disease treatment specialist Vectura (LON:VEC) to ‘buy’ from ‘hold’ on the back of today’s interims, which it stated were largely in line with consensus. The broker said: “With assets set to be filed by partner Novartis in Q4 2014, we think...
Register now for FREE Vectura Group company news